128 related articles for article (PubMed ID: 36567211)
1. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
Lee HC; Ramasamy K; Weisel K; Abonour R; Hardin JW; Rifkin RM; Ailawadhi S; Terebelo HR; Durie BGM; Tang D; Joshi P; Liu L; Jou YM; Che M; Hernandez G; Narang M; Toomey K; Gasparetto C; Wagner LI; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):112-122. PubMed ID: 36567211
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study.
Dhanasiri S; Hollier-Hann G; Stothard C; Dhanda DS; Davies FE; Rodriguez-Otero P
Clin Ther; 2021 Nov; 43(11):1983-1996.e3. PubMed ID: 34736769
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab.
Richter J; Anupindi VR; Yeaw J; Kudaravalli S; Zavisic S; Shah D
J Oncol Pharm Pract; 2022 Mar; 28(2):395-409. PubMed ID: 33611973
[TBL] [Abstract][Full Text] [Related]
4. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.
Rifkin RM; Jagannath S; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Parikh K; Abouzaid S; Srinivasan S; Kitali A; Zafar F; Abonour R
Clin Ther; 2018 Jul; 40(7):1193-1202.e1. PubMed ID: 30007443
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Madduri D; Hagiwara M; Parikh K; Pelletier C; Delea TE; Kee A; Chari A
Future Oncol; 2021 Feb; 17(5):503-515. PubMed ID: 33522834
[No Abstract] [Full Text] [Related]
7. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone.
Hagiwara M; Panjabi S; Sharma A; Delea TE
J Med Econ; 2019 Aug; 22(8):818-829. PubMed ID: 31046501
[No Abstract] [Full Text] [Related]
8. Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.
Iida S; Nakakoji M; Spanopoulos D; Okazuka K; Parulekar V; Ishida T
Future Oncol; 2022 Nov; ():. PubMed ID: 36331578
[TBL] [Abstract][Full Text] [Related]
9. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Abonour R; Wagner L; Durie BGM; Jagannath S; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Kitali A; Gibson CJ; Srinivasan S; Swern AS; Rifkin RM
Ann Hematol; 2018 Dec; 97(12):2425-2436. PubMed ID: 30056582
[TBL] [Abstract][Full Text] [Related]
10. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Roussel M; Moreau P; Hebraud B; Laribi K; Jaccard A; Dib M; Slama B; Dorvaux V; Royer B; Frenzel L; Zweegman S; Klein SK; Broijl A; Jie KS; Wang J; Vanquickelberghe V; de Boer C; Kampfenkel T; Gries KS; Fastenau J; Sonneveld P
Lancet Haematol; 2020 Dec; 7(12):e874-e883. PubMed ID: 33242444
[TBL] [Abstract][Full Text] [Related]
13. Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
Visram A; De La Torre A; White D; Su J; Masih-Khan E; Chu M; Jimenez-Zepeda V; McCurdy A; LeBlanc R; Song K; Mian H; Louzada M; Sebag M; Bergstrom D; Stakiw J; Reiman A; Kotb R; Aslam M; Venner C; Kaedbey R; Gul E; Reece D
Blood Cancer J; 2023 Dec; 13(1):181. PubMed ID: 38065967
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
16. Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data.
Sinyavskaya L; Meche A; Faucher A; Hlavacek P; Johnson SMA; DiBonaventura M; Vekeman F; Ren J; Schepart A
Curr Med Res Opin; 2024 May; 40(5):789-801. PubMed ID: 38523576
[No Abstract] [Full Text] [Related]
17. Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
Sandecka V; Pour L; Špička I; Minařík J; Radocha J; Jelínek T; Pavlíček P; Jungová A; Kessler P; Wróbel M; Štork M; Štraub J; Pika T; Čápková L; Ševčíková S; Maisnar V; Hájek R
Neoplasma; 2022 Dec; 69(6):1474-1479. PubMed ID: 36591805
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
19. Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
McCurdy A; Venner CP; Masih-Khan E; Louzada M; LeBlanc R; Sebag M; Song K; Jimenez-Zepeda VH; Kotb R; Kardjadj M; Mian H; White D; Stakiw J; Aslam M; Reiman A; Gul E; Reece D
Curr Oncol; 2022 Mar; 29(3):1575-1582. PubMed ID: 35323332
[TBL] [Abstract][Full Text] [Related]
20. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
